CONTINUE TRUSTING ALECENSA FOR PATIENTS WITH ALK+ ADVANCED NSCLC

Not a real patient.

NOW APPROVED FOR PATIENTS
with ALK+ RESECTED NSCLC1

Not a real patient.

ALECENSA has DEMONSTRATED EFFICACY

in both ALK+ RESECTED AND ADVANCED NSCLC1

ALK+ RESECTED NSCLC

ALECENSA delivered
 superior disease-free survival
vs platinum-based chemotherapy2

REDUCING
 THE RISK
 OF DISEASE
 RECURRENCE
OR DEATH BY

76%

At the time of the primary DFS analysis, in the ITT population, median DFS was not reached for ALECENSA (95% CI: NE, NE) vs 41.3 months (95% CI: 28.5, NE) for chemotherapy2

HR=0.242

(95% CI: 0.13, 0.43)
p<0.001

ALECENSA in the 

RESECTED SETTING

ALK+ ADVANCED NSCLC

ALECENSA has demonstrated 
consistent overall and intracranial 
efficacy across three Phase III trials3–5

6 out of 10

patients

WHO STARTED
1L ALECENSA

ARE STILL
ALIVE
AFTER 5 YEARS3

An exploratory post-hoc analysis conducted at ~5 years 
after randomisation of the last patient showed an OS rate of 62.5% (95% CI: 54.3, 70.8) in patients treated with ALECENSA versus 45.5% (95% CI: 33.6, 57.4) in patients treated with crizotinib3

ALECENSA in the 

ADVANCED SETTING

More than 92,000 patients treated

with ALECENSA in clinical practice6

Discover

ALECENSA

Explore

1L: first line; ALK: anaplastic lymphoma kinase; CI: confidence interval; DFS: disease-free survival; HR: hazard ratio; ITT: intention-to-treat; NE: not estimable; NSCLC: non-small cell lung cancer; 
OS: overall survival; PBRER: periodic benefit-risk evaluation report; PSUR: periodic safety update report; SmPC: Summary of Product Characteristics.

 

1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276; 3. Mok T, et al. Ann Oncol 2020;31(8):1056–1064; 4. Nakagawa K, et al. Lung Cancer 2020;139:195–199; 5. Zhou C, et al. Presented at the European Society for Medical Oncology Asia Congress (Abstract LBA11), 2–4 December, 2022, Singapore; 6. PBRER/PSUR - Roche Data on file.